<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03750565</url>
  </required_header>
  <id_info>
    <org_study_id>0176</org_study_id>
    <nct_id>NCT03750565</nct_id>
  </id_info>
  <brief_title>Multiple Dose Ethnobridging PK Study in Healthy Subjects</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Adult Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult
      Japanese and Caucasian subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Actual">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC0 t)</measure>
    <time_frame>Day 1 &amp; Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC0 24)</measure>
    <time_frame>Day 1 &amp; Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUCtau)</measure>
    <time_frame>Day 1 &amp; Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 &amp; Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration at steady state (Cmax_ss)</measure>
    <time_frame>Day 1 &amp; Day 14</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>IBD</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473 - Dose A</intervention_name>
    <description>oral capsule/tablet, QD</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473 - Dose B</intervention_name>
    <description>oral capsule/tablet, QD</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473 - Dose C</intervention_name>
    <description>oral capsule/tablet, QD</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule/tablet, QD</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For All subjects:

          -  Male or female between 18 to 55 years old

          -  Female subjects must have documentation of a negative serum pregnancy test,

          -  Female subjects must be either of non-childbearing potential or if of childbearing
             potential use a highly efficient birth control method

          -  Male subjects must be vasectomized with documented medical assessment of the surgical
             success, or use acceptable contraception

          -  All male subjects must agree to refrain from sperm donation during the study and for
             at least 7 days after the last dose of study drug.

          -  Body Mass Index (BMI) 18 to 32 kg/m2, inclusive, and weighs at least 50 kg and less
             than 90 kg

          -  Willing and able to give informed consent

          -  Additional inclusion criteria apply

        For Japanese subjects only:

          -  Subject must have been born in Japan, with 2 Japanese biological parents and 4
             Japanese grandparents as confirmed by interview.

          -  Subject has lived no longer than 10 years outside of Japan.

          -  Subject had no significant change in lifestyle, including diet, since leaving Japan.

        For Caucasian subjects only:

          -  Subject has 2 Caucasian biological parents and 4 Caucasian grandparents as confirmed
             by interview.

          -  Subject has lived no longer than 10 years outside of Europe and/or North America.

        Exclusion Criteria:

        For all subjects:

          -  Subject is a female who is pregnant, lactating, breastfeeding, or planning to become
             pregnant during the study or within 7 days after the last dose of study drug.

          -  Subject is a male who is planning to father a child during the study or within 7 days
             after the last dose of study drug.

          -  Is positive for hepatitis A, B or C, and/or HIV

          -  Has clinically significant abnormalities in baseline laboratory evaluations

          -  Subject has a clinically significant abnormal electrocardiogram (ECG)

          -  Participated in another clinical trial of an investigational drug (or medical device)
             within 30 days prior to screening or is currently participating in another trial of an
             investigational drug (or medical device) Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Japanese Subjects</keyword>
  <keyword>Healthy Caucasian Subjects</keyword>
  <keyword>Ethnobridging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

